Arcturus Therapeutics Holdings (ARCT) Operating Leases (2019 - 2026)

Arcturus Therapeutics Holdings has reported Operating Leases for 8 years, with the latest figure at $19.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 17.96% year-over-year to $19.7 million; the trailing twelve-month figure through Mar 2026 stood at $19.7 million (down 17.96% YoY), and the FY2025 full-year result was $20.8 million, down 16.86% from the prior year.
• Operating Leases for Q1 2026 stood at $19.7 million, down from $20.8 million in the prior quarter.
• The five-year high for Operating Leases was $32.2 million in Q2 2022, with the low at $4.1 million in Q1 2022.
• Historically, Operating Leases has averaged $24.9 million across 5 years, with a median of $26.0 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases declined 28.95% — and 2023, when it soared 619.42%.
• Arcturus Therapeutics Holdings' Operating Leases stood at $30.2 million in 2022, then fell by 14.26% to $25.9 million in 2023, then slipped by 3.51% to $25.0 million in 2024, then decreased by 16.86% to $20.8 million in 2025, then retreated by 5.31% to $19.7 million in 2026.
• The last three Operating Leases figures came in at $19.7 million (Q1 2026), $20.8 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.